Another Case Made for Amarin's (AMRN) Vascepa Missing NCE Status
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/18/2026
- Wall St ends lower for the day and week as chip selloff broadens
- Netflix earnings forecast disappoints Wall Street, shares tumble
- HSBC upgrades Apple to Buy, sees "strong cycle ahead"
- Kimi K3 AI breakthrough: What Wall Street analysts say about China’s OpenAI threat
- Why the Fed may still need to hike rates
- Assassin's Creed Black Flag Resynced sells 3M copies in a week
- Magnitude 7.4 earthquake strikes coast of Chiapas, Mexico; Tsunami waves are possible
- Magnitude 7.4 earthquake strikes Puerto Madero, Mexico, USGS says
- Adobe has received a takeover approach by a Big Tech company - Betaville
- Medifast launches Trilivy, replacing its Optavia brand
Amid New Patent, Amarin's (AMRN) Vascepa Might Still See Competition
October 31, 2012 11:16 AM EDTAmarin Corp. (Nasdaq: AMRN) shares are lower on the session following at least one analyst firm taking a bearish stance on its patent protection for Vascepa.
According to Summer Street analyst Bart Classen, patent coverage on Amarin's Vascepa remains "very narrow". The implication is that a generic form of... More
